Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study. Issue 2 (28th January 2019)

• Record Type: Journal Article
• Authors: Valtola, Jaakko; Silvennoinen, Raija; Ropponen, Antti; Siitonen, Timo; Säily, Marjaana; Sankelo, Marja; Putkonen, Mervi; Partanen, Anu; Pyörälä, Marja; Savolainen, Eeva-Riitta; Mäntymaa, Pentti; Pelkonen, Jukka; Jantunen, Esa; Varmavuo, Ville
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 2(2019)
• Page Start: 453
• Page End: 461
• Publication Date: 2019-01-28
• Subjects: Multiple myeloma -- autologous stem cell transplantation -- plerixafor -- graft composition -- hematological recovery -- immune recovery -- outcome; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1485911
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The composition of autologous blood grafts after cryopreservation, post-transplant hematological recovery up to 1 year and immune recovery up to 6 months as well as outcome was analyzed in 87 patients with multiple myeloma (MM). The patients receiving added plerixafor due to poor mobilization (11%) were compared to those mobilized with G-CSF or cyclophosphamide (CY) plus G-CSF. The use of plerixafor was found to significantly affect the graft composition as there was a significantly higher proportion of the more primitive CD34 + cells, higher number of T and B lymphocytes as well as NK cells in the grafts of patients who received also plerixafor. The hematological recovery after auto-SCT was comparable between the groups. The recovery of CD3 + CD4 + T cells was faster in plerixafor mobilized patients at 1 and 3 months post-transplant. There were no significant differences in progression-free (PFS) or overall survival (OS) according to the plerixafor use.